ESMO 2025

DB-11 abstract just released. In high-risk (≥T3, N+, or IBC) HER2+ eBC, neoadjuvant T-DXd-THP outperformed ddAC-THP (pCR rate 67% vs 56%, p=0.003), with reduction in cardiotoxicity (LVD 1.9 vs 9%) and low rate of ILD (4.4 vs 5.1%). The last nail in the coffin for anthracyclines.

Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next frontier → sequencing & chemo-free

#ESMO25 DESTINY-Breast11-Positive✅ but Current standard: 6× THP or TCbHP, already short & anthracycline-free. pCR ↑ 11% is notable — but if residual disease remains, then what? Will we give T-DM1, which is weaker than T-DXd? Or extrapolate from DB-05 and use adjuvant T-DXd

At #ESMO25 Ana Garrido-Castro discusses results of ASCENT-03 and TROPION-Breast02 🔸Crossover was allowed in Ascent, but not in TB02, potentially impacting OS 🔸Pts with more aggressive disease included in TB02 ➡️choice to be guided by safety profile of each ADC? @OncoAlert

📌 ✨DESTINY-Breast11✨ Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs SOC for high-risk HER2+ early breast cancer @Prof_Nadia_H Presidential Symposium #ESMO25 @OncoAlert #OncoAlertAF

Tdxd alone was not effective as NACT . I am surprised. Are u ? #destinybreast11 @dr_yakupergun @ErikaHamilton9 @myESMO

DB-11 abstract just released. In high-risk (≥T3, N+, or IBC) HER2+ eBC, neoadjuvant T-DXd-THP outperformed ddAC-THP (pCR rate 67% vs 56%, p=0.003), with reduction in cardiotoxicity (LVD 1.9 vs 9%) and low rate of ILD (4.4 vs 5.1%). The last nail in the coffin for anthracyclines.

Day 1 #ESMO25 Highlights: Breast Ca: 1. #POSITIVE 🤰 outcomes 2. #monarchE HR+ Adj Abema 3. #NATALEE HR+ Adj Ribo Lung Ca: 4. #NorthStar Local Rx in mEGFR 5. #FLAURA2 Chemo + Osi in mEGFR 6. #SOHO01 & #BeamionLung01 HER2+ NSCLC 1/12 #OncTwitter @myESMO @OncUpdates

Ask any breast oncologist today, and they’ll tell you they prefer anthracycline-free regimens in HER2-positive breast cancer — and that anthracyclines don’t improve response rates. So how did we accept a control arm containing anthracyclines in the DESTINY-Breast11 trial, which

A standing ovation moment at #ESMO25 In front of more than 9,000 cancer specialists and researchers, the Phase 3 RC48-C016 trial redefined the outlook for HER2-expressing urothelial cancer: Disitamab vedotin + Toripalimab nearly doubled overall survival over chemotherapy —

Original Article: Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer (SOHO-01 phase 1–2 study) #ESMO25 | @myESMO

#ESMO25 Managing HR+/HER2– mBC in 2025 💬An update is likely following the evERA and VIKTORIA-1 trials From Dr. William Gradishar's presentation👇

Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN showed a big EFS win for DFLOT, along with

Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next frontier → sequencing & chemo-free

HARMONi-6: In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy showed significantly improved progression-free survival compared with tislelizumab plus chemotherapy, regardless of PD-L1 status. #ESMO25

PD-1 >=50% is a very strong indicator for immunotherapy. No chemo needed is confirmed.

#ESMO25 Dr. @Ilias_Houda presents randomized phase III PAULIEN trial of 1L pembro vs chemo + pembro in PD-L1 high NSCLC. Only 72 patients, as study stopped early for futility. #ESMOAmbassadors

Ivonescimab + chemo improved PFS over tislelizumab + chemo (11.1 vs 6.9 mo, HR 0.60, p<0.0001) in 1L sq-NSCLC. Benefit seen across PD-L1 groups. Dual target strategy keeps moving, VEGF still matters. #ESMO25 @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle

In muscle-invasive bladder cancer, ctDNA-guided adjuvant atezolizumab improved disease-free and overall survival. Proud to be part of this work, with @tompowles1 and all colleagues, patients, families, and sponsors who made it real. @NEJM @myESMO #ESMO25 @OncoBellmunt

Original Article: ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (IMvigor011 phase 3 trial) #ESMO25 | @myESMO

💎 #ESMO25 Presidential Session w/ @JeanneTie #ColorectalCancer – Phase III DYNAMIC-III: ctDNA-guided de-escalation after surgery in stage III colon cancer In ctDNA⁻ patients: ☄️ 3-year RFS 85.3% vs 88.1% (standard) 🎯 Oxaliplatin exposure reduced 88.6% ➜ 34.8% 💥 Fewer

Wonderful talk by @PGrivasMDPhD on neoadj #bladdercancer treatment w updates #NIAGARA , role of ctDNA and ongoing neoadjuvant/adjuvant trials👉his take home message for our clinical practice. #ESMO25 #ESMOAmbassador @OncoAlert @myESMO

PARERE trial: Panitumumab retreatment followed by regorafenib vs the reverse sequence in chemorefractory mCRC with RAS/ BRAF WT ctDNA #ESMO25 #ESMOAmbassadors 👉 mOS: 11.6 vs 11.7mo 👉Better PFS for pani in both arms 🧐negative trial, but rechallenge is an option in 4L @myesmo

Indeed phenomenal broad impact by our friend @tompowles1 including excellent presentation @myESMO #ESMO25 evaluating the clinical utility of ctDNA in IO-naive pts with MIBC in adjuvant setting: IMvigor011 validated hypothesis generated by IMvigor010:

HARMONi-6: In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy showed significantly improved progression-free survival compared with tislelizumab plus chemotherapy, regardless of PD-L1 status. #ESMO25

Ivonescimab + chemo improved PFS over tislelizumab + chemo (11.1 vs 6.9 mo, HR 0.60, p<0.0001) in 1L sq-NSCLC. Benefit seen across PD-L1 groups. Dual target strategy keeps moving, VEGF still matters. #ESMO25 @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle

Dr. Shun Lu delivers HARMONi-6 results at #ESMO25: first line ivonescimab + chemotherapy vs tislelizumab (PD-1, approved by China, EMA) + chemo for advanced squamous NSCLC. Chemotherapy + immunotherapy is our standard of care but squamous outcomes remain poor. #ESMOAmbassadors

Akeso and Summit Tx's ivonescimab and chemo reduced the risk of progression or death by 40% compared with BeOne’s Tevimbra and chemo in Chinese patients with first-line squamous NSCLC, according to HARMONi-6 data at #ESMO25

🔥🚨@OncoAlert Hot Off The Press. Just published @TheLancet in conjunction with presentation @myESMO #ESMO25 Results of: 🎯#HARMONi-6 phase 3 trial of: ⭐️#Ivonescimab + #Chemotherapy VS #Tislelizumab + #Chemotherapy as 1st line Tx for advanced #Squamous non-small-cell

Dual-Target Breakthrough in Lung Cancer At #ESMO25, the Phase 3 HARMONi-6 trial showed that ivonescimab (PD-1 × VEGF) + chemotherapy significantly improved PFS compared with PD-1 + chemo. Although OS data are still immature, the striking PFS advantage signals that this

So, post conf season what are the biggest 2025 advances in thoracic cancers? For me #1 is T cell engager therapy (for now tarlatamab) in small cell lung cancer, #2 kras (largely based on data in panc), #3/hon mention neoadjuvant IO, old movie that keeps selling some seats! #lcsm

ENCO+CET+FOLFOX showed consistent efficacy regardless of BRAF V600E VAF at baseline. Resistance mutations in KRAS, NRAS, and MAP2K1 were more frequent in the ENCO+CET arm than in the ENCO+CET+FOLFOX arm (41% vs. 16%). 729O - ctDNA analysis from BREAKWATER #ESMO25

Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday

⭐️ Abstract 1817MO - MRD analysis from LAURA: Having +ctDNA results after curative intent therapy has been consistently shown to have negative outcomes across a variety of clinical situations. Here, we will see MRD outcomes from the very impactful LAURA study.

This is, to my eyes, one of the most exiting abstracts from @myESMO #ESMO25 #Presidential #PRAME, expressed in many tumours 😉 #AdoptiveCellTherapy achieves a 🔝ORR (67%)🥳 Proof of concept ✅ Expand concept to other tumours? New target of interest? #ESMOAmbassadors